IFF · Q2 2025 Earnings
CautiousInternational Flavors & Fragrances
Reported August 5, 2025
30-second summary
Revenue fell 4% YoY to $2.76B with comparable currency-neutral growth of 3%, and management reaffirmed FY25 ranges while signaling the low end of the 1-4% currency-neutral sales growth band — softer volumes partially offset by improved FX. The more important admission: R&D and H&B capacity investments made last year will begin contributing in 2026, building to full benefit in 2027 per management's framing. Taste (+6% CN sales) and Food Ingredients (+21% CN EBITDA, +170 bps margin to 14.6%) were the real drivers; Pharma (+21% CN sales) is a divested rump contributing only one month. Leverage hit 2.5x — the first sub-3.0x print since 2018 — and the Board authorized a new $500M share repurchase program.
Headline numbers
EPS
Q2 FY2025
$1.15
Revenue
Q2 FY2025
$2.76B
-4.3% YoY
Gross margin
Q2 FY2025
37.3%
Free cash flow
Q2 FY2025
$0.09B
Operating margin
Q2 FY2025
7.2%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $2.76B | -4.3% |
| EPS | $1.15 | — |
| Gross margin | 37.3% | — |
| Operating margin | 7.2% | — |
| Free cash flow | $0.09B | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Taste | $0.631B | +6.0% |
| Food Ingredients | $0.85B | +1.0% |
| Health & Biosciences | $0.577B | +4.0% |
| Scent | $0.603B | +1.0% |
| Pharma Solutions | $0.103B | +21.0% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Adjusted Operating EBITDA | $552M |
| Adjusted Operating EBITDA Margin | 20.0% |
| Currency Neutral Sales Growth (Comparable) | 3% |
| Currency Neutral Adjusted Operating EBITDA Growth (Comparable) | 6% |
| Net Debt to Credit Adjusted EBITDA | 2.5x |
| Taste Adjusted Operating EBITDA Margin | 19.8% |
| Health & Biosciences Adjusted Operating EBITDA Margin | 26.2% |
| Scent Adjusted Operating EBITDA Margin | 21.6% |
Management tone
The tone is notably defensive for a specialty leader that had been framing 2025 as an inflection year. Five distinct shifts are visible in this print:
Growth narrative walked toward the low end inside reaffirmed ranges. The dollar and CN ranges were reaffirmed, but management explicitly signaled the low end of the CN sales range and acknowledged "modestly softer volume expectations" partially offset by FX. The clearest statement: "we expect to be at the lower end of our one to four percent currency neutral sales growth in 2025." Visibility has degraded since Q1 even where management chose not to formally cut the range.
Innovation payoff timeline framed as 2026 ramp, 2027 full benefit. The most consequential CEO line: "despite an increasingly challenging operating environment and the time it is taking for the increased investments in R&D and in health and biosciences capacity that we started to action through last year to show up in increased sales...will begin to show more impact in 2026 and build for full benefit in 2027." Management is conceding that capital deployed in 2024 has not yet generated returns and won't for another 12-24 months — framed as the expected ramp, not a deferral.
Capital allocation reframed from balanced to defensive. On M&A: "We are very mindful of our track record in this area and we are committed to being very disciplined going forward." That's an explicit reference to historical deal performance (read: DuPont N&B) and a clear signal that bolt-ons will be small and selective. Alongside, the Board authorized a new $500M share repurchase program — sized at minimum to offset dilution (~$75-109M/yr), with flexibility to scale up when shares trade below intrinsic value. Repurchases planned to begin Q4 FY2025.
Geographic demand call sharpened. Softness in North America and China is now explicitly cited as a multi-quarter headwind, with Latin America and Europe carrying the relative strength. Taste in particular showed the divergence.
Q3 set up as the hardest quarter. Management telegraphed this on the Q1 call and reiterated it: prior-year Q3 comps (Taste +15%, H&B +12%, Scent +10%) are the high bar of 2024, and growth "will moderate, particularly in Q3."
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
David Beljeeter · Deutsche Bank
Timeline for completing strategic alternatives evaluation of food ingredients business; potential retention of portions; expected buyer interest from strategic and PE players
Management expects to update progress at Q4 earnings call with absolute clarity in 2026. Three preparatory steps completed: separation of Nourish, hiring transformation leader Andy Muller, and divesting commodities. Already receiving proactive interest from both PE and strategic buyers.
Josh Spector · UBS
Outlook for scent segment in Q3-Q4; divergent trends between fine fragrance/consumer versus fragrance ingredients; expectations for ingredient drag continuation
Fine fragrance expected to remain strong through year with double-digit growth. Consumer fragrance trending low single digits on headline but solid on 2-year basis. Fragrance ingredients to remain pressured at similar Q2 levels, with commodities (less innovation, specialty portfolio gaps) as pressure point; focus on specialty ingredients investment going forward.
Patrick Cunningham · SOTY
Strategic rationale for Bungie divestiture; disenergies assessment; margin sizing of divested business
Divesting soy crush, soy protein concentrate, and lecithin—commoditized products better run by Bungie. Business was low single-digit EBITDA margin, distracting from differentiated isolated soy protein focus. Divestiture improves food ingredients margins significantly and enables innovation focus on non-commodity segments.
Lawrence Alexander · Jeff Reiss
Sequential end-market trends in taste and scent; confidence in 2026 end-markets; innovation investment timing and contribution to 2026 performance
Taste: slowdown in US, China, Asia; Latin America and Europe strong. Fine fragrance delivering double-digit growth with recent wins supporting H2 and 2026 confidence. Consumer fragrance low single-digit with commercial pipeline strengthening and confidence in 2026 acceleration. Fragrance ingredients negative in H2, expecting flattening in 2026 and growth recovery in 2027 as specialty investments mature. Innovation pipeline contributing to 2026.
Jeff Zakakis · JP Morgan
Currency headwind commentary reconciliation with observed currency strength; hedging programs in place; food ingredients capital intensity and potential retained size post-transaction
Currency impact ~1% drag year-to-date, flipping positive in H2; emerging market currency headwinds offsetting euro strength. No hedging program in place. Food ingredients more capital intensive than taste/scent but less than health/biosciences; Bungie transaction removed highest capital-intensive commodity operations. Food ingredients viewed as standalone entity; collaboration expected with taste and health/biosciences post-transaction; no significant carve-up expected.
What to watch into next quarter
Q3 FY2025 currency-neutral growth print — management has explicitly set Q3 as the hardest comp; watch whether comparable growth holds positive given Taste, H&B, and Scent prior-year Q3 growth of 15%/12%/10%. Sub-1% would imply the FY range is in jeopardy.
Food Ingredients strategic alternatives update at Q4 FY2025 earnings — does management announce a defined process (sale vs. spin), and is a transaction value framework disclosed?
Fragrance ingredients trajectory — confirmation that the segment is flattening into Q4 FY2025 is the leading indicator for the 2026 recovery thesis; any further deterioration delays the recovery further.
H&B capacity utilization commentary — last year's H&B capacity build is the largest single piece of the innovation payoff ramp. Watch for any quantification of utilization or volume ramp.
Net leverage and buyback pacing — currently 2.5x net debt / credit-adjusted EBITDA (first sub-3.0x since 2018). $500M repurchase authorization launched with Q4 FY2025 start; watch FCF generation and whether divestiture proceeds accelerate the path further below.
Sources
- IFF Q2 FY2025 Press Release — https://www.sec.gov/Archives/edgar/data/51253/000005125325000040/q22025991pressreleaseofiff.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.